These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 3707811)

  • 41. The effect of age on the pharmacokinetics of oxprenolol.
    Kendall MJ; Quarterman CP
    Int J Clin Pharmacol Ther Toxicol; 1982 Mar; 20(3):101-4. PubMed ID: 7068281
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A comparison of single doses of bucindolol and oxprenolol in hypertensive patients.
    Webster J; Petrie JC; Robb OJ; Jamieson M; Verschueren J
    Br J Clin Pharmacol; 1985 Oct; 20(4):393-400. PubMed ID: 2866786
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Once daily beta-blocker in hypertension--oxprenolol slow-release.
    Gordon RD; Ziesak M; Rowe WS; Strakosch CR; Row G
    J Int Med Res; 1981; 9(1):6-11. PubMed ID: 7009256
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A comparison of the effects of the slow release formulations of metoprolol and oxprenolol in hypertension.
    Comerford MB; Besterman EM
    Ann Clin Res; 1982 Feb; 14(1):27-31. PubMed ID: 7137874
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oxprenolol absorption in man after single bolus dosing into two segments of the colon compared with that after oral dosing.
    Antonin KH; Bieck P; Scheurlen M; Jedrychowski M; Malchow H
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):137S-142S. PubMed ID: 4005115
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Monitoring of the plasma concentration of a beta blocker with retarded effect (Slow Trasicor, 160 mg) in humans.
    Faragó E; Mihóczy L
    Int J Clin Pharmacol Ther Toxicol; 1983 Jul; 21(7):346-9. PubMed ID: 6885205
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antihypertensive effect of a new formulation of slow release oxprenolol in essential hypertension.
    Pomidossi G; Parati G; Malaspina D; Camesasca C; Motolese M; Zanchetti A; Mancia G
    J Cardiovasc Pharmacol; 1987 Nov; 10(5):593-8. PubMed ID: 2447411
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Oxprenolol-loaded bioadhesive microspheres: preparation and in vitro/in vivo characterization.
    Preda M; Leucuta SE
    J Microencapsul; 2003; 20(6):777-89. PubMed ID: 14594666
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Slow-release oxprenolol and chlortalidone administered once daily in essential hypertension].
    Rossi A; Ziacchi V; Fracalossi C; Marino A; Lomanto B
    Minerva Cardioangiol; 1984 Dec; 32(12):949-62. PubMed ID: 6531101
    [No Abstract]   [Full Text] [Related]  

  • 50. A comparison of slow Trasicor (oxprenolol 160 mg) and Trasidrex (oxprenolol 160 mg and cyclopenthiazide 0.25 mg) in the treatment of hypertension in general practice.
    Elsdon-Dew RW; Holden E
    J Int Med Res; 1981; 9(5):315-8. PubMed ID: 7028531
    [No Abstract]   [Full Text] [Related]  

  • 51. Concentration-effect relationship of oxprenolol in healthy volunteers: a retrospective analysis.
    Racine-Poon A; Moppert J
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):143S-149S. PubMed ID: 4005116
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of oxprenolol vs methyldopa as second-line antihypertensive agents in the elderly.
    Traub YM
    Arch Intern Med; 1988 Jan; 148(1):77-80. PubMed ID: 3276279
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Atenolol, sustained-release oxprenolol, and long-acting propranolol in hypertension.
    Petrie JC; Jeffers TA; Robb OJ; Scott AK; Webster J
    Br Med J; 1980 Jun; 280(6231):1573-4. PubMed ID: 7000243
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Can once daily dosage be effective in the treatment of hypertension throughout 24 hours? A controlled evaluation of sustained release oxprenolol.
    Volan GN; Rogers HJ; House F
    Br J Clin Pharmacol; 1979 Jul; 8(1):86-9. PubMed ID: 399593
    [No Abstract]   [Full Text] [Related]  

  • 55. Excretion of oxprenolol and timolol in breast milk.
    Fidler J; Smith V; De Swiet M
    Br J Obstet Gynaecol; 1983 Oct; 90(10):961-5. PubMed ID: 6626493
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Experience with sustained-release oxprenolol (slow trasicor) in the management of hypertension in general practice.
    Forrest WA
    J Int Med Res; 1979; 7(4):318-23. PubMed ID: 488521
    [No Abstract]   [Full Text] [Related]  

  • 57. A fixed combination of oxprenolol slow-release and chlorthalidone once daily in treatment of mild to moderate hypertension.
    Muiesan G; Agabiti-Rosei E; Buoninconti R; Carotti A; Fariello R; Innocenti P; Toso M; Valori C; Motolese M
    Int J Clin Pharmacol Ther Toxicol; 1981 Jun; 19(6):249-55. PubMed ID: 7309298
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Relation between plasma concentrations and cardiovascular effects of oral oxprenolol in man.
    Brunner L; Imhof P; Jack D
    Eur J Clin Pharmacol; 1975; 8(1):3-9. PubMed ID: 786674
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Once daily administration of a beta-blocker in hypertension.
    Watt M; Duncan TD
    N Z Med J; 1978 Feb; 87(606):126-8. PubMed ID: 274648
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Oros drug delivery systems for the beta-adrenoreceptor antagonists oxprenolol and metoprolol.
    Br J Clin Pharmacol; 1985; 19 Suppl 2():63S-249S. PubMed ID: 4005131
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.